CORDIS
EU research results

CORDIS

English EN
RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities

RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities

Objective

RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mortality and morbidity, both from uncontrolled disease and treatment associated co-morbidities, like infection and malignancy. This requires the need to stratify patients by their outcome and to tailor immunosuppression based on much deeper knowledge of the mechanisms that control initiation and persistence of the pathogenic immune responses. The RELENT Consortium has been formed to generate this knowledge with the ultimate goal of developing treatments tailored to the specific needs of individual patients. RELENT combines the resources of seven leading European Investigators and two from US and Australia whose expertise is not available elsewhere in the world but necessary for the ambitious work program. Three SMEs will supply specific reagents and translate the results to biomarker development. This will enable RELENT to deliver its four specific research aims, namely to: i) Combine subset analysis of genome wide association studies with classical cell biology to uncover pathways that influence and ii) use multiplexed antigen arrays, whole proteome analysis and rapid mass analysis to identify protein signatures that predict outcome and response to treatment in chronic autoimmune disease. iii) Characterise T and B cell abnormalities that predispose to autoimmunity and infection by studying the ageing immune system in health and disease. iv) Analyse pathogenic effector T cells and their control by macrophages and dendritic cells and the molecules they secrete using in vivo models. We anticipate to identify common mechanisms responsible for the persistence and outcomes in severe autoimmune and inflammatory diseases in females and males and that the results should be rapidly translatable into clinical practice for the benefit of patients.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MEDIZINISCHE UNIVERSITAET WIEN

Address

Spitalgasse 23
1090 Wien

Austria

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 133 200,75

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 530 390

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 524 500

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 494 237,50

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 456 242,50

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 395 635

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden

EU Contribution

€ 461 250

Mayo Clinic

United States

Monash University

Australia

EMC MICROCOLLECTIONS GMBH

Germany

EU Contribution

€ 471 250

Hycult biotechnology bv

Netherlands

EU Contribution

€ 449 937,50

PHENOCELL

France

EU Contribution

€ 443 500

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 38 576

ARTTIC

France

EU Contribution

€ 211 532

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 389 180

Project information

Grant agreement ID: 668036

Status

Ongoing project

  • Start date

    1 November 2015

  • End date

    30 April 2020

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 6 469 522,50

  • EU contribution

    € 5 999 431,25

Coordinated by:

MEDIZINISCHE UNIVERSITAET WIEN

Austria